Home > Neurology > AAN 2019 > Parkinson’s Disease and other Movement Disorders > Leukaemia and hypertension therapies tested in Parkinson’s disease

Leukaemia and hypertension therapies tested in Parkinson’s disease

Presented By
Dr Charbel Moussa & Dr Tanya Simuni
Conference
AAN 2019
Results of two highly anticipated trials in Parkinson's disease were presented, of therapies already registered for indications outside of neurology. These were the broad-based tyrosine-kinase inhibitor nilotinib, registered for the treatment of chronic myeloid leukaemia (CML) and the dihydropyridine calcium channel antagonist isradipine, an approved treatment of hypertension. A single dose of nilotinib induced a change of dopamine metabolism in Parkinson’s disease patients [1].“This kind of potential treatment for Parkinson’s could increase the use of a patient’s own dopamine, instead of using or periodically increasing drugs that mimic dopamine”, explained first author Dr Charbel Moussa (Georgetown University Medical Center, Washington DC, USA). In the study she presented, 75 Parkinson’s disease patients were randomised to 5 groups to receive open-label single-dose nilotinib (150, 200, 300, or 400 mg) or placebo. Nilotinib entered the brain in a dose-ind...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on